Status:
COMPLETED
Gene Therapy for the Treatment of Brain Tumors
Lead Sponsor:
National Institute of Neurological Disorders and Stroke (NINDS)
Conditions:
Brain Neoplasm
Neoplasm Metastasis
Eligibility:
All Genders
19+ years
Phase:
PHASE1
Brief Summary
Malignant brain tumors are responsible for a significant amount of deaths in children and adults. Even with advances in surgery, radiation therapy, and chemotherapy, many patients diagnosed with a mal...
Detailed Description
Malignant brain tumors are responsible for significant morbidity and mortality in both pediatric and adult populations. These common tumors present an enormous therapeutic challenge due to their poor ...
Eligibility Criteria
- INCLUSION CRITERIA:
All adults, greater than 18 years of age, with malignant brain tumors (primary and metastatic) who failed all standard therapy for their disease will be eligible to enter the study.
EXCLUSION CRITERIA:
No pregnant women will be entered into the study.
Patients with HIV infection will not be accepted for this study.
Key Trial Info
Start Date :
August 21 1992
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 30 2010
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT00001328
Start Date
August 21 1992
End Date
April 30 2010
Last Update
July 2 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States, 20892